“Brand-name medicines’ market exclusivity periods have climbed an average of 2.2 years since the mid-1990s, steadily delaying the market arrival of generic rivals. Reversing that trend alone could save the U.S. health care system roughly $31.7 billion, according to a Matrix report commissioned by the Coalition for Affordable Prescription Drugs, a group of insurers, pharmacy benefit managers and large employers.”
WHO WE ARE
Matrix Global Advisors (MGA) is an economic policy consulting firm in Washington, DC, specializing in fiscal, health care, and tax policy matters. Drawing on years of policy experience, the MGA team writes white papers and expert reports, and offers strategic advice to our clients.